Foundayo, a new weight loss pill from Eli Lilly, is the first oral GLP-1 that doesn't require fasting. In clinical trials, people lost an average of 8-25 pounds on the drug. One man who took the pill ...

The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...

The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive ...

The Federal Drug Administration (FDA) has approved a new once-daily weight-loss pill from Eli Lilly, adding to the bevy of GLP-1 medications available in the consumer marketplace. The drug ...

Postmenopausal women may have a powerful new edge in the battle against weight gain. A Mayo Clinic study found that those using menopausal hormone therapy while taking the obesity drug tirzepatide ...

The success of GLP-1 medications has made drugs like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo) seem like a magic bullet for weight loss. But using ...

Green powders can help fill nutritional gaps while providing some health benefits, but there are caveats to consider when purchasing and adding them to your diet.

Bengaluru: A 56-year-old man from Delhi was arrested by Tumakuru police for allegedly running a sophisticated online operation selling counterfeit weight-loss powder and spurious ayurvedic products.

The FDA approved a new GLP-1 pill called Foundayo (orforglipron) for adults with obesity or who are overweight and have weight-related health issues. Unlike the Wegovy pill, Foundayo has no food or ...

Share on Pinterest The FDA has approved a new once-daily GLP-1 pill for weight loss. Image Credit: Healthline/Photo by Eli Lilly Federal regulators have approved the GLP-1 tablet Foundayo for use in ...